DataJoint, a cutting-edge platform that combines computational databases and AI to streamline data management in life sciences, neuroscience, and oncology, has closed a $4.9M Seed funding round. The round was co-led by Barcelona-based Nina Capital, Salt Lake City’s Inoca Capital Partners, and Austin-based Capital Factory, with participation from existing investors. DataJoint’s international investor base reflects the global potential of its platform, which already serves clients and partners across multiple countries.
The funding will allow DataJoint to scale operations, enhance its SaaS platform, and expand into commercial life sciences and pharmaceutical markets in both the U.S. and Europe. The platform harmonizes multimodal data sources and enables complex AI and machine learning workflows, addressing inefficiencies in data management and reproducibility that have long challenged research labs.
Over 100 laboratories, including prestigious institutions like Johns Hopkins, UCSF, Harvard, and UCL, are already using DataJoint. By automating data structuring, processing, and analysis, the platform tackles fragmented workflows, reproducibility issues, and limited collaboration. As it expands into pharma, DataJoint will continue serving Academic Medical Centers, where the platform was initially incubated.
Founder’s Journey
The company’s CTO, Dimitri Yatsenko, started his career in database engineering in Ukraine and later in the U.S., working for public safety systems and a dot-com startup. He then led teams at GE Medical Systems, focusing on surgical imaging and navigation. After joining neuroscience startup Ripple Neuro and pursuing a PhD at Baylor College of Medicine, Dimitri co-founded nView Medical. It was during these experiences that he identified the critical gap in research data management and AI workflows, leading him to create DataJoint.
Recent Milestones
DataJoint was recently selected for the 9th cohort of PharmStars, the pharma-focused global accelerator for digital health startups. Through this program, the company will explore partnerships with pharmaceutical leaders and drive innovation around its platform.
Investor Perspectives
Marta G. Zanchi, Founding Partner at Nina Capital, highlighted the platform’s transformative potential:
"DataJoint’s computational database is a game-changer for life sciences. Its ability to streamline workflows and enhance reproducibility is essential for accelerating scientific discovery and healthcare innovation."
Chris Sheffert, Managing Director at Inoca Capital, emphasized the platform’s commercial opportunity:
"From managing complex datasets to enabling actionable AI insights, DataJoint is uniquely positioned to serve commercial life sciences and pharmaceutical companies. We are excited to support the team as they scale."
About DataJoint
DataJoint provides a unified, SaaS-based database infrastructure that integrates multimodal data into automated workflows. Built on an open-source foundation, the company plans to achieve SOC2, HIPAA, and ISO27001 compliance to expand its reach in both academia and industry.
About the Investors
About PharmStars
PharmStars is a global, pharma-focused accelerator supporting digital health startups in bridging the gap between startups and pharmaceutical companies. More info at www.PharmStars.com
cloud technology axon
SEG is an independent manufacturer of medium-voltage protection relays...
